| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
|
Velikova, Galina
|
|
|
24 |
12 |
p. 1359-1374
|
article
|
| 2 |
A new generation of comprehensive precision oncology trials
|
Geoerger, Birgit
|
|
|
24 |
12 |
p. e452
|
article
|
| 3 |
An HPV vaccine from India: broadening possibilities for cervical cancer control
|
Schiller, John T
|
|
|
24 |
12 |
p. 1288-1289
|
article
|
| 4 |
Art and hope for children with cancer
|
Ebrahimpour, Fatemeh
|
|
|
24 |
12 |
p. 1319-1320
|
article
|
| 5 |
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
|
Zeng, Qinghe
|
|
|
24 |
12 |
p. 1411-1422
|
article
|
| 6 |
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
|
Dummer, Reinhard
|
|
|
24 |
12 |
p. e461-e471
|
article
|
| 7 |
Breast cancer screening: one size does not fit all
|
The Lancet Oncology,
|
|
|
24 |
12 |
p. 1287
|
article
|
| 8 |
Cancer care in Nepal after earthquake
|
Das, Manjulika
|
|
|
24 |
12 |
p. 1314
|
article
|
| 9 |
Cancer surgery: orchestrating cancer control by strengthening health systems
|
Gospodarowicz, Mary
|
|
|
24 |
12 |
p. 1297-1298
|
article
|
| 10 |
Combined cytotoxic and immune-stimulatory gene therapy for glioma
|
Zhao, Binghao
|
|
|
24 |
12 |
p. e455
|
article
|
| 11 |
Combined cytotoxic and immune-stimulatory gene therapy for glioma – Authors' reply
|
Lowenstein, Pedro R
|
|
|
24 |
12 |
p. e456
|
article
|
| 12 |
Correction to Lancet Oncol 2023; 24: 1359–74
|
|
|
|
24 |
12 |
p. e459
|
article
|
| 13 |
Correction to Lancet Oncol 2023; 24: 1219–28
|
|
|
|
24 |
12 |
p. e459
|
article
|
| 14 |
Correction to Lancet Oncol 2023; 24: 107–16
|
|
|
|
24 |
12 |
p. e459
|
article
|
| 15 |
Correction to Lancet Oncol 2023; 24: e472–518
|
|
|
|
24 |
12 |
p. e459
|
article
|
| 16 |
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
|
Mutlu Sütcüoğlu, Bengü
|
|
|
24 |
12 |
p. e457
|
article
|
| 17 |
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply
|
Aronson, S Lot
|
|
|
24 |
12 |
p. e458
|
article
|
| 18 |
Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort
|
Im, Cindy
|
|
|
24 |
12 |
p. 1434-1442
|
article
|
| 19 |
Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine
|
Salek, Marta
|
|
|
24 |
12 |
p. 1315-1318
|
article
|
| 20 |
Drug development for hepatocellular carcinoma
|
Chan, Landon L
|
|
|
24 |
12 |
p. 1292-1294
|
article
|
| 21 |
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
|
Monk, Bradley J
|
|
|
24 |
12 |
p. 1334-1348
|
article
|
| 22 |
ESMO Congress 2023
|
Dwyer, Jessica E
|
|
|
24 |
12 |
p. 1307-1308
|
article
|
| 23 |
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
|
Niemann, Carsten U
|
|
|
24 |
12 |
p. 1423-1433
|
article
|
| 24 |
Global cancer surgery: a vital service to eliminate false economy
|
Landman, Allison
|
|
|
24 |
12 |
p. 1296-1297
|
article
|
| 25 |
Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide
|
Are, Chandrakanth
|
|
|
24 |
12 |
p. e472-e518
|
article
|
| 26 |
HPV vaccine roll-out in Nigeria and Bangladesh
|
Makoni, Munyaradzi
|
|
|
24 |
12 |
p. 1311-1312
|
article
|
| 27 |
IASLC calls for clinical trials to use tobacco use data
|
Furlow, Bryant
|
|
|
24 |
12 |
p. 1309
|
article
|
| 28 |
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial
|
Sharma, Hitt
|
|
|
24 |
12 |
p. 1321-1333
|
article
|
| 29 |
Improving access to surgery for childhood cancer
|
Hagander, Lars
|
|
|
24 |
12 |
p. 1301-1302
|
article
|
| 30 |
Investing in gender equality and equitable access improves outcomes
|
Hammad, Nazik
|
|
|
24 |
12 |
p. 1302-1304
|
article
|
| 31 |
Last cancer hospital in Gaza
|
Burki, Talha
|
|
|
24 |
12 |
p. 1313
|
article
|
| 32 |
Launch of the Latin America and the Caribbean Code Against Cancer
|
Burki, Talha Khan
|
|
|
24 |
12 |
p. 1305
|
article
|
| 33 |
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
|
Llovet, Josep M
|
|
|
24 |
12 |
p. 1399-1410
|
article
|
| 34 |
Long-term efficacy of ibrutinib–venetoclax for first-line treatment in chronic lymphocytic leukaemia
|
Fink, Anna
|
|
|
24 |
12 |
p. 1294-1295
|
article
|
| 35 |
New imPACT review in Papua New Guinea
|
Das, Manjulika
|
|
|
24 |
12 |
p. 1306
|
article
|
| 36 |
New junk food legislation in Colombia
|
Burki, Talha
|
|
|
24 |
12 |
p. e460
|
article
|
| 37 |
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer
|
St Laurent, Jessica
|
|
|
24 |
12 |
p. 1291-1292
|
article
|
| 38 |
Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study
|
Schuurman, Teska N
|
|
|
24 |
12 |
p. 1349-1358
|
article
|
| 39 |
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma
|
Milrod, Charles J
|
|
|
24 |
12 |
p. e519
|
article
|
| 40 |
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK
|
Evans, Iona
|
|
|
24 |
12 |
p. 1375-1386
|
article
|
| 41 |
Proposal to lower Australia's bowel screening age limit from 50 to 45 years
|
Kirby, Tony
|
|
|
24 |
12 |
p. 1310
|
article
|
| 42 |
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
|
Taniguchi, Cullen M
|
|
|
24 |
12 |
p. 1387-1398
|
article
|
| 43 |
The challenge of improving outcomes in locally advanced cervical cancer
|
Mileshkin, Linda R
|
|
|
24 |
12 |
p. 1289-1291
|
article
|
| 44 |
The pathway for surgery as an integral part of attaining universal health coverage
|
Mikkelsen, Bente
|
|
|
24 |
12 |
p. 1298-1301
|
article
|
| 45 |
The ways we talk about cancer
|
Kinsey, Caroline A
|
|
|
24 |
12 |
p. 1318-1319
|
article
|
| 46 |
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer
|
Olivier, Timothée
|
|
|
24 |
12 |
p. e453
|
article
|
| 47 |
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer – Authors' reply
|
Leal, Ticiana
|
|
|
24 |
12 |
p. e454
|
article
|
Journal description